Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Kalaris Therapeutics Q3 2026 Results: Net Loss of $11M, Loss Narrows

Kalaris Therapeutics, Inc. (formerly AlloVir, Inc.) is a clinical-stage biotechnology company focused on its lead product candidate, TH103. The company has incurred significant losses since inception, expects continued operating losses for the foreseeable future, and recently completed a merger with AlloVir.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-11.0-11.9
EPS (diluted, $ a share)$-0.46$-0.64

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: KLRS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Kalaris Therapeutics, Inc.: key numbers

Share price
$1.43Close, Nov 17
Market cap
$34M
Shares outstanding
23.8MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Kalaris Therapeutics, Inc.

All →
7:42 AM ET 8-K
Financial Results

Kalaris Therapeutics Financial Results

Kalaris Therapeutics reported third quarter 2026 financial results, ending the period with $82.9 million in cash and marketable securities. The company announced a delay in its Phase 1b/2 study of TH103 for nAMD due to a manufacturing supply interruption, with preliminary data now expected in the second half of 2027. Despite the delay, the company successfully completed a technology transfer to a commercial-scale manufacturer and extended its cash runway into 2028.

Term
Q3 2026

“Kalaris made meaningful progress in the third quarter. We continue to enroll and dose nAMD patients in the ongoing Phase 1b/2 study. In addition to progressing the clinical trial, we have successfully completed the tech transfer to a new commercial-scale manufacturer, with initial test batches achieving the target specifications. Given the paramount importance of ensuring critical quality attributes at the scale required for Phase 3 and commercial supply, this was a significant accomplishment in Q3 and strengthens our confidence in our future clinical supply.”

Andrew Oxtoby, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.